Xiaokai Li

This inventor holds 9 USPTO granted patents and 10 published patent applications and 2 EPO patents. Top assignees: Arrowhead Pharmaceuticals, Inc., Sixth Streetlending Partners, as the Administrative Agent. Active years: 2023-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiaokai Li. Retrieved from https://idiyas.com/inventor/xiaokai-li-fbzf3zge

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 10)

% Patents Active = 77.8

EPO Patents = 2 (Patent Applications = 12)

Average Co-Inventor Count = 7.8

ph-index = 1

Company Filing History:

8 out of 102

Arrowhead Pharmaceuticals, Inc.

patents

1 out of 4

Sixth Streetlending Partners, as the Administrative Agent

patents

Years Active: 2023-2026

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12667619 - INTEGRIN TARGETING LIGANDS AND USES THEREOF (2026-06-30),

2. 12582718 - INTEGRIN TARGETING LIGANDS AND USES THEREOF (2026-03-24),

3. 12551569 - RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use (2026-02-17),

4. 12503696 - RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions thereof, and methods of use (2025-12-23),

5. 12378558 - RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use (2025-08-05),

6. 12221610 - RNAi agents for inhibiting expression of HIF-2 alpha (), compositions thereof, and methods of use (2025-02-11),

7. 11912997 - RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use (2024-02-27),

8. 11845937 - RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use (2023-12-19),

9. 11597701 - Integrin ligands and uses thereof (2023-03-07),

Title: Innovations of Xiaokai Li in RNAi Technology

Introduction

Xiaokai Li is a prominent inventor based in Middleton, WI (US), known for his significant contributions to the field of RNA interference (RNAi) technology. With a total of five patents to his name, he has made remarkable advancements in the treatment of various diseases through innovative pharmaceutical compositions.

Latest Patents

Xiaokai Li's latest patents include groundbreaking work on RNAi agents designed to inhibit the expression of complement factor B (CFB). These agents are crucial for treating diseases such as IgA nephropathy, C3 glomerulopathy, and lupus nephritis, among others. His research also encompasses RNAi agents targeting HIF-2 alpha (EPAS1), which are instrumental in treating clear cell renal cell carcinoma (ccRCC). The pharmaceutical compositions he has developed facilitate the in vivo delivery of these agents, enhancing their effectiveness in clinical applications.

Career Highlights

Xiaokai Li is currently associated with Arrowhead Pharmaceuticals, Inc., where he continues to innovate in the field of RNAi technology. His work has not only advanced scientific understanding but has also paved the way for new therapeutic strategies in treating complex diseases.

Collaborations

Some of Xiaokai Li's notable coworkers include Anthony Nicholas and Tao Pei, who contribute to the collaborative efforts in research and development at Arrowhead Pharmaceuticals.

Conclusion

Xiaokai Li's contributions to RNAi technology exemplify the impact of innovative thinking in the medical field. His patents and ongoing research hold promise for the future of disease treatment and management.

Profile summary based on public USPTO records.